PROGNOZIROVANIE TEChENIYa RAKA ENDOMETRIYa NA FONE METABOLIChESKOGO SINDROMA
N V Bochkareva , L A Kolomiets , I V Kondakova , A L Chernyshova , S L Stukanov , O V Savenkova , T V Tropina
Russian Journal of Oncology ›› 2010, Vol. 15 ›› Issue (6) : 9 -14.
PROGNOZIROVANIE TEChENIYa RAKA ENDOMETRIYa NA FONE METABOLIChESKOGO SINDROMA
Multivariate analysis of data has yielded mathematical models of prognosis for endometrial cancer (EC) patients with and without metabolic syndrome (84 and 62 subjects, respectively). A total of 77 signs, including anthropometric, clinicoanamnestic, hormonal-metabolic, and immunohistochemical parameters, and the indicators of insulin-like growth factors in the endometrial tumors, were analyzed. All the patients with EC were divided into 2 groups in accordance with individual prognosis. The criteria for good prognosis were no recurrences, metastases, or death during 60 months. Analysis of the informative criteria included into the mathematical model indicated that EC patients with metabolic syndrome are typified by the fact that the formula contains values that are either direct criteria for metabolic syndrome or values closely clinically related to metabolic syndrome (insulin resistance, the level of triglycerides, and primary infertility). The specific feature of the model was an indicator, such as disease stage, for EC patients with metabolic syndrome and the histotype and differentiation degree of a tumor for those without metabolic syndrome, which seems to be associated with the fact that it is in this group that non-endometrioid tumors are much more frequently encountered. The level of PAPP-A was one of the most informative prognostic values in patients with and without metabolic syndrome.
endometrial cancer / metabolic syndrome / prognosis
| [1] |
Анцифиров М. Б. Ожирение. Метаболический синдром. Сахарный диабет 2-го типа / Под ред. И. И. Дедова. - М., 2000. - С. 53-61. |
| [2] |
Бочкарева Н. В. Особенности метаболизма и рецепции эстрогенов при гиперпластических процессах и раке эндометрия: Дис. ... д-ра мед. наук. - Томск, 2007. |
| [3] |
Васильев Д. А., Семенова Н. В., Берштейн Л. М. // Рос. онкол. журн. - 2007. - № 3. - С. 25-28. |
| [4] |
Гранов А. М., Винокуров В. Л. Лучевая терапия в онкогинекологии и онкоурологии. - СПб., 2002. |
| [5] |
Задионченко В. С., Адашева Т. В., Демичева О. Ю. и др. // Consilium medicum. - 2005. - Т. 7, № 9. http://old.consiliummedicum.com/media/consilium/05. |
| [6] |
Квачевская Ю. О. Особенности рака эндометрия при синдроме инсулинорезистентности: Автореф. дис. ... канд. мед. наук. - СПб., 1999. |
| [7] |
Крапивина Н. А. Оптимизация лечения ожирения у женщин репродуктивного возраста: Дис. ... канд. мед. наук. - Кемерово, 2005. |
| [8] |
Чернобровкина А. Е. Клинико-патогенетическое значение содержания эстрогенов в ткани рака эндометрия: Автореф. дис. ... канд. мед. наук. - СПб., 1999. |
| [9] |
Юнкеров В. И., Григорьев С. Г. Математико-статистическая обработка данных медицинских исследований. - СПб., 2002. |
| [10] |
Bilbao C., Rodriguez G., Ramirez R. et al. // Int. J. Cancer. - 2006. - Vol. 119. - P. 563-570. |
| [11] |
Gudice L. C., Conover C. A., Bale L. et al. // J. Clin. Endocrinol. Metab. - 2002. - Vol. 87. - P. 2359-2366. |
| [12] |
Ikarashi T., Takeuchi S. // Nippon Sanka. - 1987. - Vol. 39, N 9. - P. 1634-1640. |
| [13] |
Kalli K. R., Chen B. K., Bale L. K. et al. // Int. J. Cancer. - 2004. - Vol. 110, N 5. - P. 633-640. |
| [14] |
Lacey J. V., George J., Mutter L. et al. // Cancer Res. - 2008. - Vol. 68. N 14. - P. 6014-6020. |
| [15] |
Liby K., Nelther B., Mohamet L. et al. // Breast Cancer Res. Treat. - 2003. - Vol. 79, N 2. - P. 241-252. |
| [16] |
Soroush A. R., Mahmood H., Moemeni M. et al. // BMC Cancer. - 2004. - Vol. 4. - P. 97-101. |
| [17] |
Yurkovetsky Z., Shiomo T., Steve S. et al. // Gynecol. Oncol. - 2007. - Vol. 107, N 1. - P. 58-65. |
Eco-Vector
/
| 〈 |
|
〉 |
PDF
